A Milestone for Canadian Life Sciences
Apotex Health has officially priced its highly anticipated initial public offering (IPO) at $24 per share, raising a total of $1.3 billion. The move, confirmed on June 10, 2026, represents the largest public offering on the Toronto Stock Exchange (TSX) since 2021, marking a significant milestone for the Canadian life sciences and pharmaceutical sector.
The offering was upsized from an initial target of $1 billion, reflecting strong market demand for the generic drug manufacturer’s portfolio. According to reports from The Canadian Press, the deal consists of a treasury offering of approximately 35.4 million shares—generating $850 million for the company—and a secondary offering of 18.75 million shares, totaling $450 million for existing shareholders.
Market Impact and Strategic Growth
Underwriters have been granted an over-allotment option for an additional 8.125 million shares at the offer price, which could further increase the total proceeds. The company, known for its extensive range of generic, biosimilar, and consumer health products, is expected to finalize the closing conditions by June 16, 2026.
Industry analysts view this successful debut as a positive signal for the Canadian capital markets, which have seen a relatively quiet period for large-scale IPOs in recent years. By exceeding its initial capital-raising goal, Apotex has demonstrated that institutional investor appetite remains robust for established players in the healthcare and manufacturing space, even amid broader global market volatility.